Apolipoprotein status in type 2 diabetes mellitus and its complications (Review)
- Authors:
- Puhong Zhang
- Jialin Gao
- Chun Pu
- Yao Zhang
-
Affiliations: Anhui Province Key Laboratory of Biological Macromolecules Research, Wannan Medical College, Wuhu, Anhui 241002, P.R. China, Department of Endocrinology and Genetic Metabolism, Yijishan Hospital of Wannan Medical College, Wuhu, Anhui 241002, P.R. China, Clinical Laboratory, Yijishan Hospital of Wannan Medical College, Wuhu, Anhui 241002, P.R. China - Published online on: October 19, 2017 https://doi.org/10.3892/mmr.2017.7831
- Pages: 9279-9286
This article is mentioned in:
Abstract
Ingelfinger JR and Rosen CJ: Cardiac and renovascular complications in type 2 diabetes-is there hope? N Engl J Med. 375:380–382. 2016. View Article : Google Scholar : PubMed/NCBI | |
Shulman GI: Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease. N Engl J Med. 371:1131–1141. 2014. View Article : Google Scholar : PubMed/NCBI | |
Nobécourt E, Tabet F, Lambert G, Puranik R, Bao S, Yan L, Davies MJ, Brown BE, Jenkins AJ, Dusting GJ, et al: Nonenzymatic glycation impairs the anti-inflammatory properties of apolipoprotein A-I. Arterioscler Thromb Vasc Biol. 30:766–772. 2010. View Article : Google Scholar : PubMed/NCBI | |
Younis NN, Soran H, Pemberton P, Charlton-Menys V, Elseweidy MM and Durrington PN: Small dense LDL is more susceptible to glycation than more buoyant LDL in Type 2 diabetes. Clin Sci (Lond). 124:343–349. 2013. View Article : Google Scholar : PubMed/NCBI | |
Viney NJ, van Capelleveen JC, Geary RS, Xia S, Tami JA, Yu RZ, Marcovina SM, Hughes SG, Graham MJ, Crooke RM, et al: Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): Two randomised, double-blind, placebo-controlled, dose-ranging trials. Lancet. 388:2239–2253. 2016. View Article : Google Scholar : PubMed/NCBI | |
Rye KA, Barter PJ and Cochran BJ: Apolipoprotein A-I interactions with insulin secretion and production. Curr Opin Lipidol. 27:8–13. 2016. View Article : Google Scholar : PubMed/NCBI | |
Lehti M, Donelan E, Abplanalp W, Al-Massadi O, Habegger KM, Weber J, Ress C, Mansfeld J, Somvanshi S, Trivedi C, et al: High-density lipoprotein maintains skeletal muscle function by modulating cellular respiration in mice. Circulation. 128:2364–2371. 2013. View Article : Google Scholar : PubMed/NCBI | |
Fryirs MA, Barter PJ, Appavoo M, Tuch BE, Tabet F, Heather AK and Rye KA: Effects of high-density lipoproteins on pancreatic beta-cell insulin secretion. Arterioscler Thromb Vasc Biol. 30:1642–1648. 2010. View Article : Google Scholar : PubMed/NCBI | |
Duvillard L, Dautin G, Florentin E, Jeannin A, de Barros JP Pais, Lagrost L, Petit JM, Gambert P and Vergès B: Increased apolipoprotein AI production rate and redistribution of high-density lipoprotein size induced by estrogen plus progestin as oral contraceptive. J Clin Endocrinol Metab. 94:4891–4897. 2009. View Article : Google Scholar : PubMed/NCBI | |
Bisoendial R, Tabet F, Tak PP, Petrides F, Torres LF Cuesta, Hou L, Cook A, Barter PJ, Weninger W and Rye KA: Apolipoprotein A-I limits the negative effect of tumor necrosis factor on lymphangiogenesis. Arterioscler Thromb Vasc Biol. 35:2443–2450. 2015. View Article : Google Scholar : PubMed/NCBI | |
Tabet F, Lambert G, Torres LF Cuesta, Hou L, Sotirchos I, Touyz RM, Jenkins AJ, Barter PJ and Rye KA: Lipid-free apolipoprotein A-I and discoidal reconstituted high-density lipoproteins differentially inhibit glucose-induced oxidative stress in human macrophages. Arterioscler Thromb Vasc Biol. 31:1192–1200. 2011. View Article : Google Scholar : PubMed/NCBI | |
Pu LJ, Lu L, Zhang RY, Du R, Shen Y, Zhang Q, Yang ZK, Chen QJ and Shen WF: Glycation of apoprotein A-I is associated with coronary artery plaque progression in type 2 diabetic patients. Diabetes Care. 36:1312–1320. 2013. View Article : Google Scholar : PubMed/NCBI | |
Kollerits B, Krane V, Drechsler C, Lamina C, März W, Ritz E, Wanner C and Kronenberg F: German Diabetes and Dialysis Study Investigators: Apolipoprotein A-IV concentrations and clinical outcomes in haemodialysis patients with type 2 diabetes mellitus-a post hoc analysis of the 4D Study. J Intern Med. 272:592–600. 2012. View Article : Google Scholar : PubMed/NCBI | |
Hu A, Luo Y, Li T, Guo X, Ding X, Zhu X, Wang X and Tang S: Low serum apolipoprotein A1/B ratio is associated with proliferative diabetic retinopathy in type 2 diabetes. Graefes Arch Clin Exp Ophthalmol. 250:957–962. 2012. View Article : Google Scholar : PubMed/NCBI | |
Soriguer F, Garcia-Serrano S, Garrido-Sánchez L, Gutierrez-Repiso C, Rojo-Martínez G, Garcia-Escobar E, García-Arnés J, Gallego-Perales JL, Delgado V and García-Fuentes E: Jejunal wall triglyceride concentration of morbidly obese persons is lower in those with type 2 diabetes mellitus. J Lipid Res. 51:3516–3523. 2010. View Article : Google Scholar : PubMed/NCBI | |
Galazis N, Afxentiou T, Xenophontos M, Diamanti-Kandarakis E and Atiomo W: Proteomic biomarkers of type 2 diabetes mellitus risk in women with polycystic ovary syndrome. Eur J Endocrinol. 168:R33–R43. 2013. View Article : Google Scholar : PubMed/NCBI | |
Wang W, Khan S, Blackett P, Alaupovic P and Lee E: Apolipoproteins A-I, B, and C-III in young adult Cherokee with metabolic syndrome with or without type 2 diabetes. J Clin Lipidol. 7:38–42. 2013. View Article : Google Scholar : PubMed/NCBI | |
Mendes-Lana A, Pena GG, Freitas SN, Lima AA, Nicolato RL, Nascimento-Neto RM, Machado-Coelho GL and Freitas RN: Apolipoprotein E polymorphism in Brazilian dyslipidemic individuals: Ouro Preto study. Braz J Med Biol Res. 40:49–56. 2007. View Article : Google Scholar : PubMed/NCBI | |
Charriere S, Bernard S, Aqallal M, Merlin M, Billon S, Perrot L, Le Coquil E, Sassolas A, Moulin P and Marcais C: Association of APOA5-1131T>C and S19W gene polymorphisms with both mild hypertriglyceridemia and hyperchylomicronemia in type 2 diabetic patients. Clin Chim Acta. 394:99–103. 2008. View Article : Google Scholar : PubMed/NCBI | |
Cabré A, Lázaro I, Girona J, Manzanares JM, Marimón F, Plana N, Guardiola M, Heras M and Masana L: The APOA5-1131 T>C variant enhances the association between RBP4 and hypertriglyceridemia in diabetes. Nutr Metab Cardiovasc Dis. 20:243–248. 2010. View Article : Google Scholar : PubMed/NCBI | |
Celap I, Simundic AM, Nikolac N, Kackov S and Katalinic D: Association of APOA5-1131T>C polymorphism and serum lipid levels in patients with type 2 diabetes. DNA Cell Biol. 32:589–593. 2013. View Article : Google Scholar : PubMed/NCBI | |
Sóter MO, Gomes KB, Fernandes AP, Carvalho Md, Pinheiro PS, Bosco AA, Silva DD and Sousa MO: -1131T>C and SW19 polymorphisms in APOA5 gene and lipid levels in type 2 diabetic patients. Mol Biol Rep. 39:7541–7548. 2012. View Article : Google Scholar : PubMed/NCBI | |
Brito DD, Fernandes AP, Gomes KB, Coelho FF, Cruz NG, Sabino AP, Cardoso JE, Figueiredo-Filho PP, Diamante R, Norton CR and Sousa MO: Apolipoprotein A5-1131T>C polymorphism, but not APOE genotypes, increases susceptibility for dyslipidemia in children and adolescents. Mol Biol Rep. 38:4381–4388. 2011. View Article : Google Scholar : PubMed/NCBI | |
Sørensen LP, Andersen IR, Søndergaard E, Gormsen LC, Schmitz O, Christiansen JS and Nielsen S: Basal and insulin mediated VLDL-triglyceride kinetics in type 2 diabetic men. Diabetes. 60:88–96. 2011. View Article : Google Scholar : PubMed/NCBI | |
Aslan I, Kucuksayan E and Aslan M: Effect of insulin analog initiation therapy on LDL/HDL subfraction profile and HDL associated enzymes in type 2 diabetic patients. Lipids Health Dis. 12:542013. View Article : Google Scholar : PubMed/NCBI | |
Qin B, Anderson RA, Kuzuya T, Kitaura Y and Shimomura Y: Multiple factors and pathways involved in hepatic very low density lipoprotein-apoB100 overproduction in Otsuka Long-Evans Tokushima Fatty rats. Atherosclerosis. 222:409–416. 2012. View Article : Google Scholar : PubMed/NCBI | |
Hwang YC, Ahn HY, Kim WJ, Park CY and Park SW: Increased apoB/A-I ratio independently associated with Type 2 diabetes mellitus: Cross-sectional study in a Korean population. Diabet Med. 29:1165–1170. 2012. View Article : Google Scholar : PubMed/NCBI | |
Pan J, Gao F, Bao Y, Zhang L, Tu Y and Jia W: Non-high-density lipoprotein cholesterol is associated more closely with albuminuria in Chinese type 2 diabetic patients with normal renal function, compared with traditional lipid parameters. J Clin Lipidol. 6:382–387. 2012. View Article : Google Scholar : PubMed/NCBI | |
Vergès B, Guiu B, Cercueil JP, Duvillard L, Robin I, Buffier P, Bouillet B, Aho S, Brindisi MC and Petit JM: Retinol-binding protein 4 is an independent factor associated with triglycerides and a determinant of very low-density lipoprotein-apolipoprotein B100 catabolism in type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol. 32:3050–3057. 2012. View Article : Google Scholar : PubMed/NCBI | |
Taskinen MR, Barter PJ, Ehnholm C, Sullivan DR, Mann K, Simes J, Best JD, Hamwood S and Keech AC: FIELD study investigators: Ability of traditional lipid ratios and apolipoprotein ratios to predict cardiovascular risk in people with type 2 diabetes. Diabetologia. 53:1846–1855. 2010. View Article : Google Scholar : PubMed/NCBI | |
Dahlén EM, Bjarnegard N, Länne T, Nystrom FH and Ostgren CJ: Sagittal abdominal diameter is a more independent measure compared with waist circumference to predict arterial stiffness in subjects with type 2 diabetes-a prospective observational cohort study. Cardiovasc Diabetol. 12:552013. View Article : Google Scholar : PubMed/NCBI | |
Chan DC, Wong AT, Yamashita S and Watts GF: Apolipoprotein B-48 as a determinant of endothelial function in obese subjects with type 2 diabetes mellitus: Effect of fenofibrate treatment. Atherosclerosis. 221:484–489. 2012. View Article : Google Scholar : PubMed/NCBI | |
Mancera-Romero J, Sánchez-Chaparro MA, Rioja J, Ariza MJ, Olivecrona G, González-Santos P and Valdivielso P: Fasting apolipoprotein B48 is a marker for peripheral arterial disease in type 2 diabetes. Acta Diabetol. 50:383–389. 2013. View Article : Google Scholar : PubMed/NCBI | |
Béliard S, Nogueira JP, Maraninchi M, Lairon D, Nicolay A, Giral P, Portugal H, Vialettes B and Valéro R: Parallel increase of plasma apoproteins C-II and C-III in Type 2 diabetic patients. Diabet Med. 26:736–739. 2009. View Article : Google Scholar : PubMed/NCBI | |
Caron S, Verrijken A, Mertens I, Samanez CH, Mautino G, Haas JT, Duran-Sandoval D, Prawitt J, Francque S, Vallez E, et al: Transcriptional activation of apolipoprotein CIII expression by glucose may contribute to diabetic dyslipidemia. Arterioscler Thromb Vasc Biol. 31:513–519. 2011. View Article : Google Scholar : PubMed/NCBI | |
Onat A, Hergenc G, Ayhan E, Uğur M, Kaya H, Tuncer M and Can G: Serum apolipoprotein C-III in high-density lipoprotein: A key diabetogenic risk factor in Turks. Diabet Med. 26:981–988. 2009. View Article : Google Scholar : PubMed/NCBI | |
Lee SJ, Campos H, Moye LA and Sacks FM: LDL containing apolipoprotein CIII is an independent risk factor for coronary events in diabetic patients. Arterioscler Thromb Vasc Biol. 23:853–858. 2003. View Article : Google Scholar : PubMed/NCBI | |
Hiukka A, Stahlman M, Pettersson C, Levin M, Adiels M, Teneberg S, Leinonen ES, Hultén LM, Wiklund O, Oresic M, et al: ApoCIII-enriched LDL in type 2 diabetes displays altered lipid composition, increased susceptibility for sphingomyelinase, and increased binding to biglycan. Diabetes. 58:2018–2026. 2009. View Article : Google Scholar : PubMed/NCBI | |
Singh P, Singh M, Gaur S and Kaur T: The ApoAI-CIII-AIV gene cluster and its relation to lipid levels in type 2 diabetes mellitus and coronary heart disease: Determination of a novel susceptible haplotype. Diab Vasc Dis Res. 4:124–129. 2007. View Article : Google Scholar : PubMed/NCBI | |
Onat A, Erginel-Unaltuna N, Coban N, Cicek G and Yüksel H: APOC3-482C>T polymorphism, circulating apolipoprotein C-III and smoking: Interrelation and roles in predicting type-2 diabetes and coronary disease. Clin Biochem. 44:391–396. 2011. View Article : Google Scholar : PubMed/NCBI | |
van Hoek M, van Herpt TW, Dehghan A, Hofman A, Lieverse AG, van Duijn CM, Witteman JC and Sijbrands EJ: Association of an APOC3 promoter variant with type 2 diabetes risk and need for insulin treatment in lean persons. Diabetologia. 54:1360–1367. 2011. View Article : Google Scholar : PubMed/NCBI | |
Dorfmeister B, Cooper JA, Stephens JW, Ireland H, Hurel SJ, Humphries SE and Talmud PJ: The effect of APOA5 and APOC3 variants on lipid parameters in European Whites, Indian Asians and Afro-Caribbeans with type 2 diabetes. Biochim Biophys Acta. 1772:355–363. 2007. View Article : Google Scholar : PubMed/NCBI | |
Smith CE, Tucker KL, Scott TM, Van Rompay M, Mattei J, Lai CQ, Parnell LD, Junyent M, Lee YC, Garcia-Bailo B and Ordovás JM: Apolipoprotein C3 polymorphisms, cognitive function and diabetes in Caribbean origin Hispanics. PLoS One. 4:e54652009. View Article : Google Scholar : PubMed/NCBI | |
Lim W, Bae H and Song G: Differential expression of apolipoprotein D in male reproductive system of rats by high-fat diet. Andrology. 4:1115–1122. 2016. View Article : Google Scholar : PubMed/NCBI | |
Dassati S, Waldner A and Schweigreiter R: Apolipoprotein D takes center stage in the stress response of the aging and degenerative brain. Neurobiol Aging. 35:1632–1642. 2014. View Article : Google Scholar : PubMed/NCBI | |
Hansen L, Gaster M, Oakeley EJ, Brusgaard K, Nielsen EM Damsgaard, Beck-Nielsen H, Pedersen O and Hemmings BA: Expression profiling of insulin action in human myotubes: Induction of inflammatory and pro-angiogenic pathways in relationship with glycogen synthesis and type 2 diabetes. Biochem Biophys Res Commun. 323:685–695. 2004. View Article : Google Scholar : PubMed/NCBI | |
Baker WA, Hitman GA, Hawrami K, McCarthy MI, Riikonen A, Tuomilehto-Wolf E, Nissinen A, Tuomilehto J, Mohan V, Viswanathan M, et al: Apolipoprotein D gene polymorphism: A new genetic marker for type 2 diabetic subjects in Nauru and south India. Diabet Med. 11:947–952. 1994. View Article : Google Scholar : PubMed/NCBI | |
Vijayaraghavan S, Hitman GA and Kopelman PG: Apolipoprotein-D polymorphism: A genetic marker for obesity and hyperinsulinemia. J Clin Endocrinol Metab. 79:568–570. 1994. View Article : Google Scholar : PubMed/NCBI | |
Miranda LF, Gomes KB, Tito PA, Silveira JN, Pianetti GA, Byrro RM, Peles PR, Pereira FH, Santos TR, Assini AG, et al: Clinical response to donepezil in mild and moderate dementia: Relationship to drug plasma concentration and CYP2D6 and APOE genetic polymorphisms. J Alzheimers Dis. 55:539–549. 2017. View Article : Google Scholar : PubMed/NCBI | |
Okamoto N, Morikawa M, Amano N, Yanagi M, Takasawa S and Kurumatani N: Effects of tooth loss and the apolipoprotein E ε4 Allele on mild memory impairment in the Fujiwara-kyo study of Japan: A Nested Case-Control Study. J Alzheimers Dis. 55:575–583. 2017. View Article : Google Scholar : PubMed/NCBI | |
Anthopoulos PG, Hamodrakas SJ and Bagos PG: Apolipoprotein E polymorphisms and type 2 diabetes: A meta-analysis of 30 studies including 5423 cases and 8197 controls. Mol Genet Metab. 100:283–291. 2010. View Article : Google Scholar : PubMed/NCBI | |
Tan KC, Shiu SW, Wong Y, Wong WK and Tam S: Plasma apolipoprotein E concentration is an important determinant of phospholipid transfer protein activity in type 2 diabetes mellitus. Diabetes Metab Res Rev. 22:307–312. 2006. View Article : Google Scholar : PubMed/NCBI | |
Reis KA, Ebinc FA, Koc E, Demirci H, Erten Y, Güz G, Derici UB, Bali M, Söylemezoğlu O, Arınsoy T and Sindel S: Association of the angiotensinogen M235T and APO E gene polymorphisms in Turkish type 2 diabetic patients with and without nephropathy. Ren Fail. 33:469–474. 2011. View Article : Google Scholar : PubMed/NCBI | |
Monastiriotis C, Papanas N, Trypsianis G, Karanikola K, Veletza S and Maltezos E: The ε4 allele of the APOE gene is associated with more severe peripheral neuropathy in type 2 diabetic patients. Angiology. 64:451–455. 2013. View Article : Google Scholar : PubMed/NCBI | |
Al-Majed HT, Qasem JA, Al-Sherifi AK, Al-Attar AA, Qasem AA and Abdullah SA: Association between apolipoprotein E-polymorphism and Ischemic heart disease patients with or without type 2 diabetes mellitus: A preliminary study in Kuwait. Arch Iran Med. 14:385–388. 2011.PubMed/NCBI | |
Vaisi-Raygani A, Rahimi Z, Tavilani H and Pourmotabbed T: Butyrylcholinesterase K variant and the APOE-ε4 allele work in synergy to increase the risk of coronary artery disease especially in diabetic patients. Mol Biol Rep. 37:2083–2091. 2010. View Article : Google Scholar : PubMed/NCBI | |
Chaudhary R, Likidlilid A, Peerapatdit T, Tresukosol D, Srisuma S, Ratanamaneechat S and Sriratanasathavorn C: Apolipoprotein E gene polymorphism: Effects on plasma lipids and risk of type 2 diabetes and coronary artery disease. Cardiovasc Diabetol. 11:362012. View Article : Google Scholar : PubMed/NCBI | |
Winkler K, Hoffmann MM, Krane V, März W, Drechsler C and Wanner C: Apolipoprotein E genotype predicts cardiovascular endpoints in dialysis patients with type 2 diabetes mellitus. Atherosclerosis. 208:197–202. 2010. View Article : Google Scholar : PubMed/NCBI | |
Irie F, Fitzpatrick AL, Lopez OL, Kuller LH, Peila R, Newman AB and Launer LJ: Enhanced risk for Alzheimer disease in persons with type 2 diabetes and APOE epsilon4: The Cardiovascular Health Study Cognition Study. Arch Neurol. 65:89–93. 2008. View Article : Google Scholar : PubMed/NCBI | |
Dore GA, Elias MF, Robbins MA, Elias PK and Nagy Z: Presence of the APOE epsilon4 allele modifies the relationship between type 2 diabetes and cognitive performance: The Maine-Syracuse Study. Diabetologia. 52:2551–2560. 2009. View Article : Google Scholar : PubMed/NCBI | |
Kempf SJ, Janik D, Barjaktarovic Z, Braga-Tanaka I III, Tanaka S, Neff F, Saran A, Larsen MR and Tapio S: Chronic low-dose-rate ionising radiation affects the hippocampal phosphoproteome in the ApoE-/-Alzheimer's mouse model. Oncotarget. 7:71817–71832. 2016.PubMed/NCBI | |
Zhang P, Gao J, Pu C, Feng G, Wang L, Huang L, Tao Q and Zhang Y: Effects of hyperlipidaemia on plasma apolipoprotein M levels in patients with type 2 diabetes mellitus: An independent case-control study. Lipids Health Dis. 15:1582016. View Article : Google Scholar : PubMed/NCBI | |
Zhang H, Pluhackova K, Jiang Z and Böckmann RA: Binding Characteristics of Sphingosine-1-Phosphate to ApoM hints to assisted release mechanism via the ApoM Calyx-opening. Sci Rep. 6:306552016. View Article : Google Scholar : PubMed/NCBI | |
Ooi EM, Watts GF, Chan DC, Nielsen LB, Plomgaard P, Dahlbäck B and Barrett PH: Association of apolipoprotein M with high-density lipoprotein kinetics in overweight-obese men. Atherosclerosis. 210:326–330. 2010. View Article : Google Scholar : PubMed/NCBI | |
Kurano M, Tsukamoto K, Hara M, Ohkawa R, Ikeda H and Yatomi Y: LDL receptor and ApoE are involved in the clearance of ApoM-associated sphingosine 1-phosphate. J Biol Chem. 290:2477–2488. 2015. View Article : Google Scholar : PubMed/NCBI | |
Qu X, Zhao S, Gao J, Hu M, Dong L and Zhang X: Reduced expression and secretion of apolipoprotein M in fat-fed, streptozotocin-diabetic rats is partially reversed by an artificial ligand of PPARγ. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 37:796–801. 2012.(In Chinese). PubMed/NCBI | |
Zhang PH, Gao JL, Pu C, Feng G, Wang LZ, Huang LZ and Zhang Y: A single-nucleotide polymorphism C-724/del in the proter region of the apolipoprotein M gene is associated with type 2 diabetes mellitus. Lipids Health Dis. 15:1422016. View Article : Google Scholar : PubMed/NCBI | |
Zhang PH, Gao JL, Pu C, Feng G, Wang L, Huang L and Zhang Y: ApoM/HDL-C and apoM/apoA-I ratios are indicators of diabetic nephropathy in healthy controls and type 2 diabetes mellitus. Clin Chim Acta. 466:31–37. 2017. View Article : Google Scholar : PubMed/NCBI | |
Niu N, Zhu X and Liu Y, Du T, Wang X, Chen D, Sun B, Gu HF and Liu Y: Single nucleotide polymorphisms in the proximal promoter region of apolipoprotein M gene (apoM) confer the susceptibility to development of type 2 diabetes in Han Chinese. Diabetes Metab Res Rev. 23:21–25. 2007. View Article : Google Scholar : PubMed/NCBI | |
Zhang Z, Chu G and Yin RX: Apolipoprotein M T-778C polymorphism is associated with serum lipid levels and the risk of coronary artery disease in the Chinese population: A meta-analysis. Lipids Health Dis. 12:1352013. View Article : Google Scholar : PubMed/NCBI | |
Zhou JW, Tsui SK, Ng MC, Geng H, Li SK, So WY, Ma RC, Wang Y, Tao Q, Chen ZY, et al: Apolipoprotein M gene (APOM) polymorphism modifies metabolic and disease traits in type 2 diabetes. PLoS One. 6:e173242011. View Article : Google Scholar : PubMed/NCBI | |
Guo H, Zhao XX, Zhang XJ, Chen W and Zhang J: Functional study of −724I/D polymorphism in apolipoprotein M (apoM) gene promoter region and its association with myocardial infarction. Med Sci Monit. 21:371–375. 2015. View Article : Google Scholar : PubMed/NCBI |